The burden of cardiovascular disease (CVD) in patients with diabetes has long been recognised.1 As CVD is the leading cause of death and morbidity in patients with type 2 diabetes, managing cardiovascular risk is a key priority.2 The United States Food and Drug Administration (FDA) has mandated that cardiovascular safety of new diabetes medicines be investigated. Several trials unexpectedly showed not only cardiovascular safety, but also additional cardiovascular and renal benefits over placebo. These results are creating a paradigm shift in diabetes management. Cardiovascular and renal benefits are now considered in the medicine decision pathway.

Learning objectives

After successful completion of this CPD activity, pharmacists should be able to:

  • Describe the significance of cardiovascular disease as a macrovascular complication of diabetes
  • Summarise patient and medicine factors to be considered when selecting diabetes medicines
  • Explain the results of recent cardiovascular safety trials and their impact on diabetes management.

Competencies (2016) addressed: 1.1, 1.3, 1.5, 3.5

Accreditation number: CAP1907B

Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.

Cardiovascu

THIS IS A CPD ARTICLE. YOU NEED TO BE A PSA MEMBER AND LOGGED IN TO READ MORE.